Clementia Pharmaceuticals (CMTA) BidaskScore is downgraded to Held

Clementia Pharmaceuticals

The BidaskScore of Clementia Pharmaceuticals CMTACMTA shows that the shares of the company are now CMTAStrongly Bought Held by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Held since March 5.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company´s lead product candidate palovarotene is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO palovarotene could become the standard of care in either or both of these indications.

Clementia Pharmaceuticals

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.